Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
33 studies found for:    nivolumab | Open Studies
Show Display Options
Rank Status Study
1 Recruiting PH 1 Biomarker Study of Nivolumab and Ipilimumab and Nivolumab in Combination With Ipilimumab in Advanced Melanoma
Conditions: Advanced Melanoma;   Metastatic Melanoma
Interventions: Biological: Nivolumab;   Drug: Ipilimumab
2 Recruiting Safety Study in Nivolumab Alone and in Combination With Ipilimumab or Lirilumab in Lymphoma and Multiple Myeloma
Conditions: Non-Hodgkin's Lymphoma;   Hodgkin Lymphoma;   Multiple Myeloma
Interventions: Biological: Nivolumab;   Biological: Ipilimumab;   Biological: Lirilumab
3 Recruiting Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012)
Condition: Non-small Cell Lung Cancer
Interventions: Biological: Nivolumab;   Drug: Gemcitabine;   Drug: Cisplatin;   Drug: Pemetrexed;   Drug: Paclitaxel;   Drug: Carboplatin;   Drug: Bevacizumab;   Drug: Erlotinib;   Biological: Ipilimumab
4 Recruiting Study of the Safety and Tolerability of Urelumab Administered in Combination With Nivolumab in Solid Tumors and B-cell Non-Hodgkins Lymphoma
Conditions: Advanced Solid Tumors;   Advanced B-cell NHL
Interventions: Biological: Urelumab;   Biological: Nivolumab
5 Not yet recruiting Nivolumab in Eliminating Minimal Residual Disease and Preventing Relapse in Patients With Acute Myeloid Leukemia in Remission After Chemotherapy
Conditions: Adult Acute Myeloid Leukemia in Remission;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)
Interventions: Biological: nivolumab;   Other: clinical observation;   Other: laboratory biomarker analysis
6 Not yet recruiting Nivolumab vs Nivolumab + Bevacizumab vs Nivolumab + Ipilimumab in Metastatic Renal Cell Carcinoma (mRCC)
Condition: Kidney Cancer
Interventions: Drug: Nivolumab;   Drug: Bevacizumab;   Drug: Ipilimumab
7 Not yet recruiting GVAX Pancreas Vaccine (With CY) and CRS-207 With or Without Nivolumab
Condition: Previously Treated Metastatic Adenocarcinoma of the Pancreas
Interventions: Biological: CRS-207;   Biological: GVAX;   Drug: nivolumab;   Drug: CY
8 Recruiting A Phase 1B Study to Investigate the Safety and Preliminary Efficacy for the Combination of Dasatinib Plus Nivolumab in Patients With Chronic Myeloid Leukemia
Condition: Chronic Myeloid Leukemia
Interventions: Drug: Dasatinib;   Drug: Nivolumab
9 Recruiting A Phase I Study of an Anti-KIR Antibody in Combination With an Anti-PD1 Antibody in Patients With Advanced Solid Tumors
Condition: CANCER,NOS
Interventions: Drug: Lirilumab;   Drug: Nivolumab
10 Not yet recruiting Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
Conditions: Cervical Adenocarcinoma;   Cervical Adenosquamous Cell Carcinoma;   Cervical Squamous Cell Carcinoma;   Recurrent Cervical Cancer;   Stage IVA Cervical Cancer;   Stage IVB Cervical Cancer
Interventions: Biological: nivolumab;   Other: laboratory biomarker analysis
11 Recruiting A Phase 1/2, Open-label Study of Nivolumab Monotherapy or Nivolumab Combined With Ipilimumab in Subjects With Advanced or Metastatic Solid Tumors
Condition: Advanced or Metastatic Solid Tumors
Interventions: Biological: Nivolumab;   Biological: Ipilimumab
12 Recruiting A Phase I Trial of a Vaccine Combining Multiple Class I Peptides and Montanide ISA 51VG With Escalating Doses of Anti-PD-1 Antibody Nivolumab or Ipilimumab With Nivolumab For Patients With Resected Stages IIIC/ IV Melanoma
Condition: Melanoma (Skin)
Interventions: Biological: NY-ESO-1 157-165 (165V);   Drug: Nivolumab;   Biological: gp100:280-288 (288V);   Drug: Montanide ISA 51 vegetable grade (VG);   Drug: Ipilimumab;   Procedure: Apheresis Procedure
13 Recruiting A Study of Nivolumab and Nivolumab Plus Ipilimumab in Recurrent and Metastatic Colon Cancer (CheckMate 142)
Conditions: MSI Positive Colorectal Cancer;   MSI Negative Colorectal Cancer
Interventions: Drug: Ipilimumab;   Drug: Nivolumab
14 Recruiting A Randomized Study of Nivolumab Versus Bevacizumab and a Safety Study of Nivolumab or Nivolumab Combined With Ipilimumab in Adult Subjects With Recurrent Glioblastoma (GBM) (CheckMate 143)
Condition: Recurrent Glioblastoma
Interventions: Biological: Nivolumab;   Biological: Ipilimumab;   Biological: Bevacizumab
15 Recruiting An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026)
Condition: Stage IV or Recurrent Non-Small Cell Lung Cancer
Interventions: Biological: Nivolumab;   Drug: Gemcitabine;   Drug: Cisplatin;   Drug: Carboplatin;   Drug: Paclitaxel;   Drug: Pemetrexed
16 Recruiting Neoadjuvant Anti-PD-1, Nivolumab in Resectable NSCLC
Condition: Non-Small Cell Lung Cancer
Intervention: Drug: Nivolumab
17 Not yet recruiting ONO-4538 Phase I Study in Patients With Solid Tumor
Conditions: Advanced Solid Tumors;   Recurrent Solid Tumors
Intervention: Drug: ONO-4538
18 Recruiting A Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least One Prior Systemic Regimen (CheckMate 153)
Condition: Non Small Cell Lung Cancer (NSCLC)
Intervention: Drug: Nivolumab
19 Recruiting Study of Nivolumab in Subjects With Hodgkin's Lymphoma (Registrational) (CheckMate 205)
Condition: Hodgkin Disease
Intervention: Drug: Nivolumab
20 Recruiting Study of Nivolumab in Subjects With Relapsed or Refractory Follicular Lymphoma (FL) (CheckMate 140)
Condition: Lymphoma
Intervention: Drug: Nivolumab

   Previous Page Studies Shown (1-20) Next Page (21-33) Show next page of results    Last Page
Indicates status has not been verified in more than two years